Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Erie
    4. ›
  4. 14057
    5. ›
  5. IMMUNE MODULATORY THERAPIES LLC

IMMUNE MODULATORY THERAPIES LLC

Company Details

Name: IMMUNE MODULATORY THERAPIES LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 16 Jul 2015 (10 years ago)
Entity Number: 4790398
ZIP code: 14057
County: Erie
Place of Formation: New York
Address: 4786 ENSER ROAD, EDEN, NY, United States, 14057

DOS Process Agent

Name Role Address
RICHARD B. BANKERT DOS Process Agent 4786 ENSER ROAD, EDEN, NY, United States, 14057

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:
immunemodulatorytherapies.us
Phone Number:
716-713-5772
E-mail Address:
tiberius_14226@yahoo.com
Contact Person:
ROBERT CHAU
Ownership and Self-Certifications:
Veteran
User ID:
P2778676

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
J453G5R8UMJ5
CAGE Code:
7F0L2
UEI Expiration Date:
2024-12-07

Business Information

URL:
immunemodulatorytherapies.us
Activation Date:
2023-12-12
Initial Registration Date:
2015-07-26

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
7F0L2
Status:
Obsolete
Type:
Non-Manufacturer
CAGE Update Date:
2024-03-11
SAM Expiration:
2024-12-07

Contact Information

POC:
ROBERT CHAU
Phone:
+1 716-713-5772

Filings

Filing Number Date Filed Type Effective Date
190718060106 2019-07-18 BIENNIAL STATEMENT 2019-07-01
180326006050 2018-03-26 BIENNIAL STATEMENT 2017-07-01
151019000591 2015-10-19 CERTIFICATE OF PUBLICATION 2015-10-19
150716000193 2015-07-16 ARTICLES OF ORGANIZATION 2015-07-16

USAspending Awards / Financial Assistance

Date:
2021-03-11
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NOVEL DRUG FOR CANCER IMMUNOTHERAPY THAT TARGETS PHOSPHATIDYLSERINE - ABSTRACT PHOSPHATIDYLSERINE (PS) IS EMERGING AS AN ATTRACTIVE IMMUNOTHERAPEUTIC TARGET IN THE LIGHT OF MOUNTING EVIDENCE HIGHLIGHTING ITS CAUSAL LINK TO IMMUNE SUPPRESSION. WE HAVE ESTABLISHED THAT EXOSOMES DERIVED FROM MELANOMA AND OVARIAN TUMOR MICROENVIRONMENTS EXPRESS PS ON THEIR SURFACES AND SUPPRESS MULTIPLE ACTIVATION ENDPOINTS OF T CELLS TRIGGERED THROUGH THE T CELL RECEPTOR. STUDIES HAVE ALSO SHOWN THAT EXPRESSION OF PS ON THE SURFACE OF MANY NON-APOPTOTIC CANCER CELLS LEAD TO IMMUNOSUPPRESSION. RECENT CLINICAL STUDIES IN MELANOMA PATIENTS DEMONSTRATED THAT EXOSOMES THAT ARE RELEASED FROM PATIENT TUMORS SUPPRESS T CELL TUMOR KILLING AND CONTRIBUTE TO TUMOR PROGRESSION. WE HAVE DESIGNED AND SYNTHESIZED A NEW COMPOUND, ZN-DPA)6-DP-15K (EXOBLOCK) THAT BINDS TO PHOSPHATIDYLSERINE WITH HIGH AVIDITY. EXOBLOCK WAS SHOWN TO CONSISTENTLY AND SIGNIFICANTLY BLOCK THE IMMUNE SUPPRESSIVE ACTIVITY OF EXOSOMES DERIVED FROM MELANOMA AND OVARIAN TUMOR MICROENVIRONMENTS IN VITRO. BASED UPON THESE FINDINGS, WE PREDICTED THAT EXOBLOCK WOULD ENHANCE THE KILLING OF TUMOR CELLS BY T CELLS IN TUMOR XENOGRAFTS DUE TO ITS BINDING TO PS ON THE EXOSOMES, TUMOR AND APOPTOTIC CELLS, REPRESENTING A MULTI- PRONGED APPROACH. WE TESTED THIS PREDICTION USING TWO DIFFERENT HUMAN TUMOR XENOGRAFT MODELS: A) THE PREVIOUSLY VALIDATED IN-HOUSE DEVELOPED OMENTAL TUMOR XENOGRAFT (OTX) MODEL ESTABLISHED USING PATIENT-DERIVED OVARIAN TUMORS, AND B) THE RECENTLY DEVELOPED AND VALIDATED XENOMIMETIC MOUSE (X-MOUSE) MODEL THAT ALLOWS US TO QUANTIFY AND ESTABLISH THE EFFICACY OF MULTIPLE T CELL-STIMULATING IMMUNE-BASED THERAPIES PRE-CLINICALLY. THIS MODEL USES MELANOMA PATIENT-DERIVED TUMOR-SPECIFIC T CELLS THAT ARE ADOPTIVELY TRANSFERRED INTO IMMUNODEFICIENT MICE BEARING MELANOMA XENOGRAFTS EXPRESSING TUMOR NEO-ANTIGENS RECOGNIZED BY THE T CELLS. THE THERAPEUTIC EFFICACY OF EXOBLOCK WAS NEXT ESTABLISHED BY SIGNIFICANTLY ENHANCING TUMOR SUPPRESSION IN BOTH THE OTX AND X- MOUSE MODELS, AND WAS FOUND TO BE COMPARABLE TO ANTI-PD-1 THERAPY IN X-MOUSE MODEL. TOGETHER, THESE RESULTS HAVE LAID THE FOUNDATION AND RATIONALE FOR OUR WORK PROPOSED IN THE PHASE I APPLICATION. ADDITIONAL TOXICITY AND PHARMACOKINETIC (PK) STUDIES ARE PROPOSED FOR EXOBLOCK IN AIM 1. THE PK STUDIES WILL HELP TO DETERMINE THE OPTIMAL DOSE, SCHEDULE AND DELIVERY METHOD OF EXOBLOCK THAT WILL BE TESTED IN AIM 2. IN AIM 2 EXOBLOCK WILL BE TESTED IN VIVO FOR ITS THERAPEUTIC EFFICACY IN OMENTAL TUMOR XENOGRAFT (OTX) MODEL CONSISTING OF PATIENT-DERIVED OVARIAN TUMOR AND SYNGENEIC MOUSE MELANOMA MODEL WITH B16-F10 TUMOR. OUR RATIONALE FOR USING BOTH A HUMAN AND MOUSE TUMOR MODEL IS DISCUSSED IN THE APPROACH. THE RESULTS OF THIS PHASE 1 STUDY WILL LAY THE FOUNDATION FOR A MORE EXTENSIVE STUDY IN A FUTURE PHASE 2 STUDY THAT WILL LEAD TO AN IND AND CLINICAL TRIAL OF EXOBLOCK.
Obligated Amount:
293173.22
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-02-09
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
15946.00
Total Face Value Of Loan:
15946.00
Date:
2020-04-11
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
12800.00
Total Face Value Of Loan:
12800.00
Date:
2018-04-13
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
REVERSING/BLOCKING T CELL SUPPRESSION BY EXTRACELLULAR VESICLES AS CANCER THERAPY
Obligated Amount:
280919.18
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Date Approved:
2020-04-11
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
12800
Current Approval Amount:
12800
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
12876.1
Date Approved:
2021-02-09
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
15946
Current Approval Amount:
15946
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
16035.12

Related by officers

RICHARD B. BANKERT

WAKEROBIN BIOTECHNOLOGIES LLC

Related by address

4786 ENSER ROAD, EDEN, NY, United States, 14057

WAKEROBIN BIOTECHNOLOGIES LLC XENOMIMETICS LLC T. & B. BIOCLONE, INC.

Date of last update: 25 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated